DaVita Inc.

NYSE:DVA 주식 리포트

시가총액: US$12.0b

DaVita 향후 성장

Future 기준 점검 2/6

DaVita (는) 각각 연간 6.9% 및 4.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 84% 로 예상됩니다.

핵심 정보

6.9%

이익 성장률

17.14%

EPS 성장률

Healthcare 이익 성장17.8%
매출 성장률4.8%
향후 자기자본이익률84.01%
애널리스트 커버리지

Good

마지막 업데이트06 Aug 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jul 29

DVA: GLP-1 Headwinds And Overvaluation Will Pressure Future Stock Economics

Analysts have lifted the DaVita fair value estimate from $193.71 to $208.57, reflecting updated price targets that point to sector tailwinds, ongoing growth investments, and expectations for continued benefits from technology and care delivery initiatives. Analyst Commentary Recent research on DaVita points to a mixed but generally constructive tone, with most Street commentary focused on how the company executes on growth initiatives and manages valuation after the latest round of price target increases.
Seeking Alpha • Jul 25

Davita: Valuation Is Nearing Resistance Level

Summary Davita currently trades near the upper end of its historical valuation channel. Valuation levels suggest DVA may be approaching overvalued territory relative to its historical norms. Investors should monitor for potential mean reversion if DVA's valuation remains elevated. This positioning may warrant caution or profit-taking for those with existing positions. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 15

DVA: AI Kidney Care Platform Will Drive Future Earnings Repricing

Analysts have lifted the DaVita fair value estimate from $179.66 to $270.00, citing a series of higher price targets up to $270 and research that highlights sector tailwinds, ongoing growth investments, and company specific initiatives around advanced dialysis technologies, GLP-1 use, and home care services. Analyst Commentary Recent research updates around DaVita point to a more constructive tone, with several bullish analysts revising their fair value views higher and emphasizing the potential impact of company execution on advanced dialysis technologies, GLP-1 integration, and home care efforts.
내러티브 업데이트 • Jun 30

DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside

DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.
내러티브 업데이트 • Jun 16

DVA: Share Repurchases And GLP-1 Risks Will Shape Future Stock Economics

DaVita's analyst price target has been raised by $57, with analysts citing updated assumptions around discount rates, long term revenue growth, profit margin, and future P/E as key drivers of the revised valuation view. Analyst Commentary Recent research on DaVita highlights a cluster of upward price target revisions and an upgrade, with analysts revisiting their assumptions on discount rates, long term revenue growth, profit margins, and future P/E multiples.
내러티브 업데이트 • Jun 02

DVA: Share Repurchases And GLP-1 Headwinds Will Shape Future Kidney Care Economics

DaVita’s updated analyst price target holds steady at $193.71, with recent upward revisions from firms like TD Cowen, Truist, Barclays and an upgrade at Deutsche Bank. These moves reflect analysts’ focus on its refined discount rate, revenue growth outlook, profit margin assumptions and expected future P/E multiple.
내러티브 업데이트 • May 13

DVA: Buybacks And Revised Earnings Assumptions Will Confront Emerging GLP-1 Headwinds

DaVita's analyst price target has shifted from $151.71 to $193.71, with analysts pointing to updated assumptions for revenue growth, profit margins and future P/E multiples, along with a series of recent target hikes and an upgrade from major firms as key drivers behind the change. Analyst Commentary Recent Street research on DaVita has been active, with several firms revisiting their models and adjusting targets.
내러티브 업데이트 • Apr 28

DVA: Buybacks And Earnings Assumptions Will Shape Future Return Balance

Analysts have raised DaVita's consolidated price target by $30 to $151.71, citing updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research on DaVita has centered on higher price targets and refreshed assumptions around discount rates, revenue outlook, margins and future P/E multiples.
내러티브 업데이트 • Apr 07

DVA: Buyback Pace And Long Term Earnings Assumptions Will Shape Future Returns

Analysts raised their DaVita price targets by up to $30, citing updated assumptions for discount rates and long term earnings multiples, while keeping core fair value drivers broadly unchanged. Analyst Commentary Recent research updates around DaVita have focused on recalibrating valuation frameworks rather than shifting the core business thesis.
내러티브 업데이트 • Mar 23

DVA: Ongoing Buybacks And Revised P/E Assumptions Will Shape Future Returns

DaVita’s analyst price target has been revised to $151.71, with analysts pointing to updated assumptions around the discount rate and forward P/E as key drivers of the refreshed outlook. Analyst Commentary Recent Street research on DaVita points to a cluster of higher price targets, with several firms revisiting their models around discount rates and forward P/E assumptions.
내러티브 업데이트 • Mar 08

DVA: Ongoing Buybacks And Repriced Execution Risk Will Shape Future Returns

Our updated analyst price target for DaVita edges higher by a few dollars to reflect slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E, generally in line with the recent series of upward target revisions from Truist, TD Cowen, UBS and Barclays. Analyst Commentary Bullish Takeaways Bullish analysts raising price targets by US$4 to US$30 signal increased confidence in DaVita's ability to execute against current expectations rather than a complete reset of the story.
내러티브 업데이트 • Feb 21

DVA: Buybacks And Richer P/E Assumptions Will Shape Future Return Potential

Analysts have raised their DaVita fair value estimate from $147.75 to $151.71, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E following a series of recent price target increases from major research firms. Analyst Commentary Recent price target changes from several firms point to a reappraisal of DaVita's risk and reward profile, which feeds directly into the updated fair value estimate.
분석 기사 • Feb 06

Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely

DaVita Inc. ( NYSE:DVA ) shares have had a really impressive month, gaining 30% after a shaky period beforehand. Not...
내러티브 업데이트 • Feb 05

DVA: Updated Cash Returns And Margin Assumptions Will Shape Future Upside Potential

Our DaVita view now reflects a higher fair value estimate of $147.75, up from $143.00. Analysts point to updated assumptions on discount rate, revenue growth, margin profile, and a lower future P/E as key drivers behind the price target revisions across recent Street reports.
내러티브 업데이트 • Jan 22

DVA: Share Repurchases And Kidney Research Pipeline Will Support Future Upside

Analysts have kept their fair value estimate for DaVita steady at US$143.00. They cited only small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their outlook.
내러티브 업데이트 • Jan 07

DVA: Clinical Research Pipeline And Buybacks Will Support Earnings Despite Reimbursement Headwinds

Analysts have trimmed their price target for DaVita by about $1.50 to $143, reflecting slightly higher discount rate and P/E assumptions while keeping growth and margin expectations broadly in line. What's in the News DaVita plans to unveil six new studies at the American Society of Nephrology's Kidney Week 2025 in Houston, focused on dialysis treatments, middle molecule clearance, access to transplantation and end of life care (Key Developments).
내러티브 업데이트 • Dec 20

DVA: Clinical Initiatives And Buybacks Will Support Earnings Despite Reimbursement Headwinds

Analysts modestly raised their price target on DaVita to about $145 per share, reflecting slightly lower discount rate assumptions and a marginally improved long term earnings outlook, while maintaining stable fair value and growth expectations. What's in the News DaVita will unveil six new clinical studies at ASN Kidney Week 2025 in Houston, including an oral presentation on GLP-1 receptor agonist use and its association with lower hospitalization rates in end stage kidney disease patients (company announcement).
내러티브 업데이트 • Dec 06

DVA: Hospital Fundamentals Will Support Earnings Amid Tougher Reimbursement Outlook

Analysts have modestly reduced their price target on DaVita to $140 from $145, reflecting increased concern about a more challenging policy and reimbursement environment, despite generally solid hospital fundamentals. Analyst Commentary Analyst sentiment around DaVita remains mixed, with modestly reduced price targets reflecting both confidence in the company’s operational footing and caution about the evolving reimbursement backdrop.
내러티브 업데이트 • Nov 22

DVA: Hospital Fundamentals And Resilient Execution Will Drive Steady Performance

DaVita’s analyst price target has been revised downward from $147.13 to $144.50, as analysts cite a cautious outlook due to anticipated policy and reimbursement challenges, despite otherwise steady hospital fundamentals. Analyst Commentary Analysts have offered a range of perspectives on DaVita following the recent adjustment to its price target.
내러티브 업데이트 • Nov 03

DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025

DaVita's analyst price target has been reduced from $150.50 to $147.13, as analysts cite ongoing concerns over policy headwinds and recent operational challenges that are impacting forecasts. Analyst Commentary Analysts have updated their outlook on DaVita based on recent sector-wide developments and company-specific events.
내러티브 업데이트 • Oct 20

Aging Population And AI Will Reshape Dialysis Care

DaVita's analyst price target has been revised downward from $153.50 to $150.50. This change reflects ongoing concerns among analysts about reimbursement challenges and the impact of recent operational disruptions.
내러티브 업데이트 • Sep 04

Aging Population And AI Will Reshape Dialysis Care

Analysts have revised their outlook on DaVita to reflect lower treatment growth, reduced revenue per treatment, and ongoing operational challenges stemming from cyberattack disruptions, resulting in a consensus price target that remains unchanged at $153.50. Analyst Commentary Bearish analysts revised down treatment growth expectations due to higher missed treatment rates stemming from cyberattack disruptions.
Seeking Alpha • Mar 17

The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin

Summary Between 2016 and 2024, DaVita's revenues grew less proportionally than the U.S. inflation. DVA has experienced difficulty enrolling more patients in its dialysis program, reporting a decline in its patients since 2019. Since 2012, the company has experienced lawsuits, which have cost approximately $1,000 million in payments and have negatively affected its reputation. The net income of DaVita increased by 50.59% between 2017 and 2024. In the last year, the company reported an 11.66% net income margin. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

DaVita: Momentum Could Fade Given High Valuation

Summary DaVita has returned ~60% over the last year, backed by superior earnings growth; however, going forward, I believe earnings growth should slow down. The Company faces headwinds from supply chain issues, higher mortality rates, and increased interest expenses, but tailwinds from lower center closure costs and Latin America acquisitions should more than offset headwinds. DVA stock is currently trading at a premium compared to the historical average. Applying a 14x PE multiple to the 2025 consensus EPS of $11.44, I estimate a fair value of $160 per share, below the current $177. Read the full article on Seeking Alpha
Seeking Alpha • Nov 14

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

Summary Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach. I assign DaVita a price target of $130/share, reflecting a cautious outlook on growth and valuation amidst industry and economic uncertainties. Read the full article on Seeking Alpha
User avatar
새로운 내러티브 • Aug 22

Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons

DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.

이익 및 매출 성장 예측

NYSE:DVA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202815,2031,077N/AN/A3
12/31/202714,6141,016N/AN/A6
12/31/202614,146933881N/A6
6/30/202614,0108221,6102,193N/A
3/31/202613,8357561,4932,027N/A
12/31/202513,6437221,3111,887N/A
9/30/202513,3187721,2921,893N/A
6/30/202513,1618361,2881,862N/A
3/31/202512,9698601,7592,337N/A
12/31/202412,8169361,4672,022N/A
9/30/202412,6678281,4161,960N/A
6/30/202412,5248601,2691,810N/A
3/31/202412,3388169201,462N/A
12/31/202312,1406921,4912,059N/A
9/30/202311,9115961,3141,918N/A
6/30/202311,7394541,3571,967N/A
3/31/202311,6655001,0771,705N/A
12/31/202211,6105479611,565N/A
9/30/202211,6376801,1521,751N/A
6/30/202211,6278349951,607N/A
3/31/202211,6169031,4792,099N/A
12/31/202111,6199781,2891,931N/A
9/30/202111,5809841,2091,886N/A
6/30/202111,5668831,1241,802N/A
3/31/202111,5297911,1081,773N/A
12/31/202011,5517831,3041,979N/A
9/30/202011,5448321,5062,175N/A
6/30/202011,5248241,6482,333N/A
3/31/202011,487816N/A2,834N/A
12/31/201911,388705N/A2,496N/A
9/30/201911,311623N/A2,235N/A
6/30/201911,253548N/A2,011N/A
3/31/201911,300551N/A1,208N/A
12/31/201811,412616N/A1,531N/A
9/30/201811,378617N/A1,592N/A
6/30/201811,299698N/A1,679N/A
3/31/201811,110652N/A1,470N/A
12/31/201710,884909N/A1,966N/A
9/30/20177,7731,065N/A1,983N/A
6/30/20178,7321,480N/A2,016N/A
3/31/20179,7471,382N/A2,391N/A
12/31/201610,6961,038N/A1,988N/A
9/30/201614,550716N/A1,918N/A
6/30/201614,347361N/A2,061N/A
3/31/201614,065478N/A1,576N/A
12/31/20159,973323N/A1,531N/A
9/30/201513,565484N/A1,051N/A

애널리스트 향후 성장 전망

수입 대 저축률: DVA 의 연간 예상 수익 증가율(6.9%)이 saving rate(3.7%)보다 높습니다.

수익 vs 시장: DVA 의 연간 수익(6.9%)이 US 시장(16.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: DVA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: DVA 의 수익(연간 4.8%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: DVA 의 수익(연간 4.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: DVA의 자본 수익률은 3년 후 84%로 매우 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/06 20:22
종가2026/08/06 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

DaVita Inc.는 28명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Matthew GillmorBaird
Sarah JamesBarclays
Andrew MokBarclays